Trial Profile
Multicenter, retrospective study of denosumab in patients with bone metastases from renal cell carcinoma treated with anti angiogenic therapy.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Dec 2016
Price :
$35
*
At a glance
- Drugs Denosumab (Primary)
- Indications Bone metastases
- Focus Adverse reactions
- 06 Dec 2016 New trial record
- 11 Oct 2016 Results assessing safety and efficacy of denosumab in bone metastases patients treated with anti-angiogenic drugs, presented at the 41st European Society for Medical Oncology Congress